This opinion cited by 28 cases:
Catalyst Pharmaceuticals, Inc. v. Xavier Becerra ( 2021 )
In Re ACTOS End-Payor Antitrust Litigation ( 2017 )
Apotex, Inc. v. Food & Drug Administration , 393 F.3d 210 ( 2004 )
Spectrum Pharmaceuticals, Inc v. Sylvia Burwell , 824 F.3d 1062 ( 2016 )
Novartis Pharm Corp. v. Leavitt, Michael O. , 435 F.3d 344 ( 2006 )
Teva Pharmaceuticals, USA, Inc. v. Leavitt , 548 F.3d 103 ( 2008 )
Janssen Pharmaceutica, NV v. Apotex, Inc. , 540 F.3d 1353 ( 2008 )
Enterprise National Bank v. Vilsack , 568 F.3d 229 ( 2009 )
Jubilant Draximage Inc. v. United States International Trade Commission ( 2019 )
Grace v. William Barr ( 2020 )
In re: FBOP Execution Protocol Cases ( 2020 )
Mylan Laboratories Limited v. Food and Drug Administration , 910 F. Supp. 2d 299 ( 2012 )
Watson Laboratories, Inc. v. Sebelius ( 2012 )
Sault Ste. Marie Tribe of Chippewa Indians v. Debra Haaland ( 2022 )
Hi-Tech Pharmacal Co. v. United States Food & Drug Administration , 587 F. Supp. 2d 1 ( 2008 )
Apotex Inc. v. U.S. Food & Drug Administration , 508 F. Supp. 2d 78 ( 2007 )
Alphapharm Pty Ltd. v. Thompson , 330 F. Supp. 2d 1 ( 2004 )
Ranbaxy Laboratories, Ltd. v. Leavitt , 459 F. Supp. 2d 1 ( 2006 )
Mutual Pharmaceutical Co., Inc. v. Pfizer, Inc. , 307 F. Supp. 2d 88 ( 2004 )
Teva Pharmaceuticals, Industries, Ltd. v. Food & Drug Administration , 355 F. Supp. 2d 111 ( 2004 )
